Single-dose 7.2mg Semaglutide (Wegovy) Pen Approved for Adult Obesity
Summary
The MHRA approved a new single-dose 7.2mg semaglutide (Wegovy) pen for adult patients with obesity (BMI ≥30kg/m²). The approval consolidates the maximum weekly dose into one injection rather than three separate 2.4mg doses. Starting dose is 0.25mg weekly, gradually increasing every four weeks as prescribed. The agency will continue monitoring safety and effectiveness.
What changed
The MHRA approved a new single-dose 7.2mg semaglutide (Wegovy) pen for treating adult patients with obesity who have a BMI of 30kg/m² or higher. This represents a more convenient delivery method for the maximum weekly dose, previously requiring three 2.4mg injections on the same day using standard pens.
Healthcare providers prescribing weight management treatments should note the new single-injection option for patients requiring the 7.2mg maximum dose. Patients should use the medicine as prescribed and report any side effects through the Yellow Card scheme. The MHRA will continue monitoring safety and effectiveness of the product.
What to do next
- Monitor for updates on product labeling and safety information
- Report suspected side effects to the MHRA Yellow Card scheme
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
News story
Single-dose 7.2mg semaglutide (Wegovy) pen approved to treat adult patients with obesity
As with any medicine, the MHRA will keep the safety and effectiveness of Wegovy under close review.
From: Medicines and Healthcare products Regulatory Agency Published 14 April 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 14 April 2026, approved the new single-dose 7.2mg semaglutide (Wegovy) pen to treat adult patients with obesity, who have a Body Mass Index (BMI) of 30kg/m² or higher.
Today’s approval will support adult patients with obesity by providing the option of a single-dose injection to receive the maximum weekly dose for weight loss and weight management.
The 7.2mg dose is administered via one injection.
Patients should always use this medicine exactly as their prescriber tells them and to check with their doctor, pharmacist, or nurse if they’re not sure.
This does not apply to overweight patients with a BMI of less than 30kg/m² using Wegovy for weight management or for patients using Wegovy to lower their risk of serious heart problems.
This decision follows the January 2026 authorisation of the 7.2mg maximum weekly dose, which required three 2.4mg doses administered on the same day using the standard 2.4mg pen.
When patients start using Wegovy, the starting dose is 0.25mg per week, which will be gradually increased every four weeks as required and prescribed by the appropriate healthcare professional. The maximum dose is 7.2mg per week.
As with any medicine, the MHRA will keep the safety and effectiveness of Wegovy under close review. Anyone who suspects they are having a side effect from this medicine are encouraged to talk to their doctor, pharmacist or nurse and report it directly to the Yellow Card scheme, either through the website (https://yellowcard.mhra.gov.uk/) or by searching the Google Play or Apple App stores for MHRA Yellow Card.
Notes to editors
- More information can be found in the Summary of Product Characteristics and Patient Information leaflets which will be published on the MHRA Products website within 7 days of approval.
- For more information on obesity and weight management visit the NHS website
Share this page
The following links open in a new tab
Updates to this page
Published 14 April 2026
Related changes
Get daily alerts for MHRA Publications
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from MHRA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when MHRA Publications publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.